> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# UroGen's Quarterly Loss Shrinks To $1.5 Million As ZUSDURI Sales Hit $68.0 Million, But JELMYTO Outlook Drops
- URL: https://www.bullished.co/urogens-quarterly-loss-shrinks-to-1-5-million-as-zusduri-sales-hit-68-0-million-but-96268ef3/
- Published: 2026-11-04T13:21:04.000Z
- Updated: 2026-11-04T13:21:04.000Z
- Description: The cancer drugmaker cut its 2026 JELMYTO sales forecast to about $90 million even as total third-quarter revenue reached $89.0 million.
- Author: Matteo Parrino
- Tags: Earnings, URGN, Industry: Healthcare

UroGen Pharma, which develops and sells treatments for urothelial and specialty cancers, cut its net loss to [$1.5 million](https://www.sec.gov/Archives/edgar/data/0001668243/000143774926034769/ex%5F1036873.htm?ref=bullished.co) in the third quarter from $33.3 million a year earlier, as sales of its new bladder cancer drug ZUSDURI took off. The company also lowered its 2026 revenue guidance for its older drug, JELMYTO, in an [8-K filed](https://www.sec.gov/Archives/edgar/data/0001668243/000143774926034769/urgn20261026%5F8k.htm?ref=bullished.co) Wednesday.

## ZUSDURI drives a $89.0 million quarter

Total revenue was $89.0 million, against $27.5 million in the third quarter of 2025, and the company attributed the increase to the continued launch of ZUSDURI. The loss narrowed to $0.03 per share from $0.69.

ZUSDURI brought in $68.0 million, 35% above the second quarter. Operating income was $8.3 million, against a $27.4 million operating loss a year earlier; interest costs, financing on a prepaid forward obligation to RTW Investments, and taxes then produced the small net loss.

As of September 30, ZUSDURI had 662 unique prescribers, up from 452 at the end of June. Repeat prescribers rose to 331 from 204, about 50% of the total, up from 45%. Activated sites of care reached 1,538 from 1,444.

CEO Liz Barrett said repeat use and community adoption "reinforce our confidence in the long-term commercial opportunity."

## JELMYTO guidance cut to about $90 million

JELMYTO revenue was $21.0 million, down from $25.7 million a year earlier. Third-quarter results included a one-time unfavorable adjustment of about $1.5 million tied to a Centers for Medicare and Medicaid Services invoice for the discarded drug program, and competing clinical-trial enrollment affected patient starts in low-grade upper tract cancer.

Full-year JELMYTO revenue guidance is now about $90 million, compared with a prior range of $97 million to $101 million. Operating expense guidance of $260 million to $270 million is unchanged, with spending expected toward the upper end.

R&D expenses were $26.0 million, up from $14.0 million, and SG&A rose to $47.2 million from $37.6 million. Cash and marketable securities totaled $90.5 million at September 30, down from $120.5 million at the end of 2025.

## Pipeline: UGN-103 decision date set

The FDA accepted the application for UGN-103, a next-generation mitomycin formulation for the same bladder cancer, and set a June 14, 2027 target decision date. A new patent is expected to cover ZUSDURI into July 2044.

UroGen plans to start the late-stage LONGVIEW-HR trial of UGN-103 in high-risk bladder cancer in the fourth quarter, enrolling about 300 patients. It also dosed the first patient in an early-stage trial of UGN-501, an investigational oncolytic virus.

In August, UroGen agreed to invest up to $7 million in IntraGel Therapeutics, $4 million of it in the third quarter. Management holds its earnings call at 10:00 a.m. ET Wednesday.

The next dated milestone is the FDA's June 14, 2027 target date on UGN-103.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — UroGen Pharma Ltd. (URGN)](https://www.sec.gov/Archives/edgar/data/0001668243/000143774926034769/urgn20261026%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex\_1036873.htm — UroGen Pharma Ltd. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001668243/000143774926034769/ex%5F1036873.htm?ref=bullished.co) — SEC EDGAR